Global venture capital firm Index Ventures closed its latest life sciences fund, at nearly $117m.
The new vehicle, called Index Ventures Life VII (Jersey) LP, had previously held a first $66.5m first close in July 2015.
According to a regulatory filing with the SEC, 12 unnamed investors participated in the offering.
Index had closed a €150m fund from limited partners including GlaxoSmithKline (GSK) and the venture capital affiliate of the Janssen pharmaceutical companies of Johnson & Johnson. Have a look at the firm’s life sciences portfolio here